<DOC>
	<DOCNO>NCT02816437</DOCNO>
	<brief_summary>This pilot feasibility study determine whether fecal microbiota transplantation ( FMT ) suppress reverse gastrointestinal carriage MDROs hospitalize solid organ transplant recipient history one MDRO infection .</brief_summary>
	<brief_title>FMT MDRO Colonization Solid Organ Transplant</brief_title>
	<detailed_description>This pilot feasibility study determine whether fecal microbiota transplantation ( FMT ) suppress reverse gastrointestinal carriage MDROs hospitalize solid organ transplant recipient history one MDRO infection . Study participant meet inclusion/exclusion criterion provide write , informed consent provide pre-FMT stool sample . Participants follow time enrollment 3 month post FMT . Specific organisms interest test stool culture include vancomycin resistant enterococcus , carbapenem resistant Enterobacteriaceae carbapenem resistant Pseudomonas . Eligible patient demonstrate colonization positive culture specific organism interest give FMT . One FMT dose retention rectal enema ( OpenBiome ) administer nurse supervised principal investigator and/or sub-investigators trained performance FMT . Stool sample study participant collect analyzed follow : - Pre-FMT : Stool collection &amp; storage glycerol/flash frozen , ship dry ice - 48 hour post FMT : Stool collection use RNA later kit provide OpenBiome ( hospital ) - Day 7 : Stool collection &amp; storage glycerol/flash frozen , ship dry ice - Day 14 : Stool collection use RNAlater kit ( home ) - Day 30 : Stool collection &amp; storage glycerol/flash frozen ( hospital clinic ) , ship dry ice - Day 90 : follow-up visit clinic , final sample collect use RNAlater kit</detailed_description>
	<criteria>Inclusion Criteria Age â‰¥18 year old Solid organ transplant recipient : liver , intestinal , multivisceral transplant , heart , lung , pancreas kidney transplant recipient Transplant recipient least &gt; 30 day post solid organtransplant Transplant recipient must available locally follow 6months post FMT transplant Inpatient status time FMT History least one treat infection last 90 day ( bacteremia , UTI , pneumonia abdominal collection positive culture MDRO ) due MDRO MDRO likely enteric origin ( carbapenem resistant enterobacteriaceae ( CRE ) , vancomycin resistant enterococci ( VRE ) carbapenem resistant Pseudomonas ( CRP ) . Be without active infection &gt; 15 day : bacteremia , UTI , pneumonia abdominal collection . Be without positive culture ( except stool ) MDRO ( carbapenem resistant enterobacteriaceae ( CRE ) , vancomycin resistant enterococci ( VRE ) carbapenem resistant Pseudomonas ( CRP ) Patients receive antimicrobial ( therapeutic suppressive ) within 48 hour FMT Solid organ prophylactic antimicrobial per protocol hold 24 hour 14 day post FMT e.g . trimethoprim/sulfamethoxazole 3x/week dapsone 100 mg PO daily weekly PJP prophylaxis Ganciclovir valgancyclovir CMV prophylaxis require per protocol continue . Patients positive surveillance rectal culture evidence colonization . Exclusion Criteria Inability provide inform consent Physiciandocumented , severe allergy nut food allergens Patients allergies ingredient Generally Recognized As Safe `` glycerol , sodium chloride Study participant hospitalize intensive care unit CMV IgG , EBV IgG PCR negative time consent Biological MELD score &gt; 28 define transplant surgeon Pregnancy inability/unwillingness use contraceptive . Autoimmune hepatitis Patients receive new solid organ transplant within last 30 day time enrollment Patients antibiotic treat active infection le 2 week time enrollment Any circulatory failure vasopressor Respiratory failure ( mechanical ventilation ) time enrollment Renal failure ( GFR &lt; 30 dialysis ) time enrollment Any active Clostridium difficile infection regardless severity Postallogeneic hematopoietic stem cell transplant recipient ANC &lt; 1000/mm3 HIV+ control well control antiretroviral therapy At increase risk peritonitis : presence intraabdominal device , peritoneal dialysis . Previous FMT Patients undergoing treatment liver organ transplant rejection Patients graft vs. host disease Patients active infection ( bacteremia , pneumonia , urinary tract infection abscess ) Life expectancy &lt; 1year post transplant Any clinical significant bleed low GI source ( define require blood transfusion , endoscopy surgical radiologic intervention ) last 30 day . Any condition physician investigator deem unsafe , feel risk outweigh potential benefit , include condition medication investigator determines put subject great risk FMT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>